SRPT Long

SRPT Long

Sarepta Therapeutics
Focused on the development of precision genetic medicines to treat rare neuromuscular
and central nervous system diseases
https://investorrelations.sarepta.com/?_ga=2.49566691.415372990.1745780982-1018978192.1745780982

Major leader in treatment
- Duchenne muscular dystrophy (Duchenne) and limb-girdle muscular dystrophies (LGMDs)
- Explore perespective produts in Gene therapy and editing

Fundamentals:
- Growing Revenue and EPS
- Trading at historical low PE
- Far below market consensus $148

Technicals
- Near low 200VWAP extension 30% discount

Read More

Share:

Latest News